Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $30.00 price objective on the stock. HC Wainwright's price target indicates a potential upside of 256.72% from the stock's previous close.
Olema Pharmaceuticals Price Performance
OLMA stock traded down $1.23 during trading hours on Wednesday, reaching $8.41. The stock had a trading volume of 2,119,334 shares, compared to its average volume of 740,302. The stock has a 50-day simple moving average of $10.97 and a 200 day simple moving average of $11.94. Olema Pharmaceuticals has a fifty-two week low of $7.68 and a fifty-two week high of $16.77. The stock has a market capitalization of $481.88 million, a PE ratio of -4.05 and a beta of 1.92.
Institutional Trading of Olema Pharmaceuticals
A number of hedge funds have recently made changes to their positions in OLMA. Conway Capital Management Inc. acquired a new stake in shares of Olema Pharmaceuticals during the 3rd quarter worth about $119,000. China Universal Asset Management Co. Ltd. lifted its position in Olema Pharmaceuticals by 67.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 11,014 shares of the company's stock worth $132,000 after acquiring an additional 4,442 shares during the last quarter. Portland Investment Counsel Inc. bought a new stake in shares of Olema Pharmaceuticals during the third quarter worth approximately $143,000. Cubist Systematic Strategies LLC acquired a new position in shares of Olema Pharmaceuticals in the second quarter valued at approximately $145,000. Finally, SG Americas Securities LLC bought a new position in shares of Olema Pharmaceuticals during the third quarter worth approximately $156,000. 91.78% of the stock is owned by institutional investors and hedge funds.
Olema Pharmaceuticals Company Profile
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
See Also
Before you consider Olema Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.
While Olema Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
